Drug Profile

Research programme: antibody drug conjugate therapeutics - VERAXA Biotech/Quadira Biosciences

Latest Information Update: 22 Jun 2021

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Quadira Biosciences; VERAXA Biotech
Class Antineoplastics; Drug conjugates; Immunoconjugates; Monoclonal antibodies
Mechanism of Action Undefined mechanism

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes
Available For Licensing Yes

18 Jun 2021 Research programme: antibody drug conjugate therapeutics - VERAXA Biotech/Quadira Biosciences is available for licensing as of 18 Jun 2021. https://veraxa.de/partners/
14 Jun 2021 VERAXA Biotech and Quadira Biosciences agree to co-develop antibody drug conjugate therapeutics for Cancer
14 Jun 2021 Early research in Cancer in Germany (unspecified route)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com